COMMUNIQUÉS West-GlobeNewswire

Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular
02/08/2018
Press Release Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertension ................................................. Study to randomize 420 patients in clinical sites across the U.S. [...]
Nicox : Initiation d'une étude de phase 2 pour le NCX 470 dans le glaucome à angle ouvert et l'hypertension oculaire
02/08/2018
Communiqué de presse Nicox : Initiation d'une étude de phase 2 pour le NCX 470 dans le glaucome à angle ouvert et l'hypertension oculaire ................................................. Etude randomisée sur 420 [...]
VALNEVA Delivers Strong IXIARO® Sales Growth and reports Further Progress on Key R&D Programs in H1
02/08/2018
Valneva Delivers Strong IXIARO ® Sales Growth and r eports Further Progress on Key R&D Programs in H1 Double-digit sales growth driven by IXIARO ® Product sales of €53.5 million in H1 2018, representing 11.4% year [...]
VALNEVA publie une forte croissance des ventes d'IXIARO® et avance sur ses programmes R&D clés au S1
02/08/2018
Valneva publie une forte croissance des ventes d'IXIARO ® et avance sur ses programmes R&D clés au S1 Croissance à deux chiffres des ventes soutenue par IXIARO ® Ventes de produits de €53,5 millions au S1 2018, [...]
argenx reports second quarter business update and half-year 2018 financial results
02/08/2018
Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT August 2, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a [...]
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
02/08/2018
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock, [...]
Precision Therapeutics Receives Approval of Delisting Request from German Stock Exchange
02/08/2018
MINNEAPOLIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery [...]
La Jolla Pharmaceutical Company to Release Second Quarter 2018 Financial Results and Host a Webcasted Conference Call on August 8, 2018
01/08/2018
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve [...]
FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
01/08/2018
Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT) SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that it will [...]
Intuitive Appoints Don Kania, Ph.D. to its Board of Directors
01/08/2018
SUNNYVALE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG), the pioneer and a global technology leader in robotic-assisted, minimally invasive surgery, today announced the appointment of [...]
Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinson’s Disease
01/08/2018
Healthy volunteer study of DNL201 meets all objectives in phase 1 clinical study, including CSF exposure levels and LRRK2 inhibition, as well as pathway engagement, at doses that were safe and well tolerated DNL201 will [...]
MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
01/08/2018
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable [...]
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01/08/2018
EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]
AxoGen, Inc. Reports 2018 Second Quarter Financial Results
01/08/2018
Q2 Revenue of $20.6 million, representing 36% growth over prior year; reiterates full year 2018 guidance ALACHUA, Fla., Aug. 01, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and [...]
Conformis Announces the first 3D Total Hip Replacement Surgeries performed at JFK Medical Center in Florida
01/08/2018
The most advanced, patient conforming hip replacement system designed to enhance operational efficiency for the surgeon and improve patient outcomes BILLERICA, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. ( [...]
Zafgen to Present at the Canaccord Genuity 38th Annual Growth Conference
01/08/2018
BOSTON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
Globus Medical Reports Second Quarter 2018 Results
01/08/2018
AUDUBON, Pa., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the second quarter ended June 30, 2018. Worldwide [...]
Inovalon Reports Second Quarter 2018 Results
01/08/2018
Second Quarter 2018 Highlights Second quarter revenue of $152.8 million Second quarter net loss of $10.5 million, resulting in net loss of $0.07 per share Second quarter Non-GAAP net income of $19.3 million, resulting [...]
AIT Therapeutics Schedules Fiscal First Quarter 2019 Financial Results Conference Call and Webcast
01/08/2018
Call scheduled for Tuesday, August 14 at 10:30am Eastern Time. NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on [...]

Pages